Merck & Co., Inc. (MRK) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $148.78 +0.54%
Revenue Growth %: +0.2%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +0.2%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Merck & Co., Inc. (NYSE: MRK) reported Q3 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $12 million versus the consensus estimate of $11.61 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Darden Restaurants falls as Q1 revenue misses expectations
- Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
